Quality of Life After Stroke Using a Telemedicine-based Stroke Network (STROKE TeleQOL)

Thomas Jefferson University

Status: Unknown

Conditions: Stroke

Treatments: Drug: Alteplase

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02447094

15D.044

Details and patient eligibility

About

To study the effect of a telemedicine model of stroke care on patient-based outcomes.

Full description

Approximately 750,000 patients suffer from ischemic stroke (AIS) annually in the United States. AIS is a a leading cause of long-term disability and the third-leading cause of mortality. Effective therapies exist to ameliorate the disability associated with AIS, but implementation of these therapies is time-sensitive. Currently, there is a shortage in health care professionals with expertise in the treatment of stroke and such expertise tends to be concentrated in large community-based or academic medical centers. To respond to this shortage, stroke networks are being organized in a "hub-and-spoke" model to facilitate the rapid delivery of time-sensitive interventions such as intravenous (i.v.) tissue plasminogen activator (tPA) or rapid evaluation for AIS. Some networks are also using telemedicine to facilitate this approach and bring the needed expertise via robotic tele-presence (RTP). Though the accuracy of stroke diagnosis and i.v. tPA utilization may be higher in RTP based networks, the impact of this model on patient's outcomes has been difficult to elucidate. To this end, meaningful validated outcome assessments are crucial to understand the impact of stroke interventions including telemedicine or RTP based networks. The objective of this study is to translate evidence-based practice of healthcare, patient-centered outcome assessments, and patient-family perceptions of delivery of care into meaningful data. This will aid in the validation of the role of interventions such as "hub-and-spoke" RTP based models in stroke care.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with suspected acute ischemic stroke (AIS)
• Age >17 years

Exclusion criteria

• Hemorrhagic strokes (ICH or SAH)
• Transient ischemic attacks (TIA)
• Trauma
• Inability to obtain informed consent
• Participation in another study

Trial design

300 participants in 2 patient groups

Exposed

Description:

AIS patients evaluated through RTP and who receive i.v. tPA

Treatment:

Drug: Alteplase

Un-exposed

Description:

AIS patients evaluated through RTP and who do not receive i.v. tPA